Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
TELA · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortTELA Bio, Inc. is loss-making, burns cash and carries heavy debt, with revenue growing (+15.8% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -42.0% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -48.4% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -223.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -43.0% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.20× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 8.82× | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -6.44× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -13.97 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -35.7% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 18.8% | 41/100 |
| Operating margin volatility | 26.0% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 24.7% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
4 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 29 | 41 | 58 | 69 | 80 |
| Gross profit | 19 | 27 | 40 | 46 | 54 |
| Research & development | 6.7 | 8.9 | 9.6 | 8.8 | 9.2 |
| Operating income | (29) | (39) | (44) | (34) | (34) |
| Interest expense | 3.6 | 4.1 | 5.2 | 5.3 | 5.2 |
| Pre-tax income | – | (44) | (47) | (38) | (39) |
| Income tax | – | – | – | (0.1) | 0.2 |
| Net income | (33) | (44) | (47) | (38) | (39) |
| Diluted EPS | −$2.30 | −$2.72 | −$2.04 | −$1.33 | −$0.83 |
| Diluted shares (millions) | 14 | 16 | 23 | 29 | 47 |
4 older years available with the 10-year history. Essential plan, from €8.25/month →
−13.97 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 11, 2026